Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
The UK Intellectual Property Office has agreed to revoke an extension to a supplementary protection certificate for immunosuppressant tocilizumab, at the request of the owners.
The US Supreme Court has declined to review Eli Lilly’s patent infringement victory against Dr Reddy’s and Hospira.
The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.